What Viatris's 8-K filings say: 8 filings, latest Nov 5, 2026
Viatris filed its latest 8-K with the SEC on Nov 5, 2026. It discusses acquisition announced, manufacturing issue and product launch.
Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn
Get Viatris' live signals in Claude or ChatGPT, or by API
What changed at Viatris this week? Use Autobound signals for viatris.com.- Filed
- Nov 5, 2026
- Filings
- 8
- Signals
- 24
Source: Autobound Signal API · 76 signals tracked for Viatris · updated
8-K · latest 10
What Viatris's 8-K filings say
- SEC EDGAR
8-K
Filed · 4 signals
Viatris to Acquire Pacira BioSciences for $36.50 Per Share or $1.65 Billion in Cash
Viatris entered into a definitive agreement to acquire all outstanding common shares of Pacira BioSciences for an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026.
$1.7B
aggregate equity value for the acquisition of Pacira BioSciences
Viatris Suspends Manufacturing at Nashik Facility Following FDA OAI Notice With $200M Revenue Impact
Viatris voluntarily suspended manufacturing at its oral solid dose facility in Nashik, India following an FDA Official Action Indicated notice and expects to resume in Q1 2027.
$100M
total revenue impact of supply constraints in Q3 2026
FDA Issues Official Action Indicated Status for Viatris Oral Solid Dose Facility in Nashik
In September, Viatris received notice that the FDA inspection classification of its Nashik, India manufacturing facility was Official Action Indicated, leading to voluntary suspension of manufacturing in October.
Viatris Launches Gwyn Lo Contraceptive Patch in U.S. Following FDA Approval
Viatris launched Gwyn Lo, a combined hormonal contraceptive patch, in the U.S.
- SEC EDGAR
8-K
Filed · 4 signals
The acquisition of Pacira will force a large-scale integration of all business functions, including IT, finance, and HR, to achieve planned synergies.
$62M
Termination fee Pacira must pay Viatris if the deal is terminated under certain circumstances, indicating significant deal commitment and scale.
Viatris to acquire Pacira BioSciences in an all-cash tender offer at $36.50 per share
Viatris is acquiring Pacira BioSciences, creating significant post-merger integration needs across IT, finance, HR, and supply chain systems.
$62M
Termination fee of $62 million payable by Pacira under certain conditions. The offer price is $36.50 per share.
The merger is contingent on passing HSR antitrust review, a process requiring significant legal and data management resources within a tight timeframe.
- SEC EDGAR
8-K
Filed · 2 signals
Viatris refinances ¥40B term loan facility, extending maturity to 2029.
Viatris secured a new three-year, ¥40 billion (approx.
$255M
¥40,000,000,000 principal amount of a new senior unsecured term loan facility, used to refinance a prior loan of the same amount. USD equivalent is approximate.
Mizuho Bank, Ltd.S&P Global RatingsMoody’s Investors Service, Inc.Fitch Ratings, Inc.
- SEC EDGAR
8-K
Filed · 2 signals
Viatris raises €650M in new debt to refinance $1.675B notes maturing in 2026
Viatris is managing a significant debt maturity of $1.675 billion due in June 2026 by issuing new notes.
$1.7B
Principal amount of senior notes due 2026 being repaid, partially funded by a new €650M debt offering.
4.25%
Interest rate on new 4.250% Senior Notes due 2033.
The Bank of New York MellonCravath, Swaine & Moore LLPNautaDutilh N.V.Parker Poe Adams & Bernstein LLP
- SEC EDGAR
8-K
Filed · 2 signals
Viatris secures new capital via debt offering underwritten by BNP Paribas, Citi, and Goldman Sachs.
Viatris is raising capital through a new debt offering, indicating funds will be available for strategic initiatives, acquisitions, or refinancing existing obligations.
BNP PARIBASCitigroup Global Markets LimitedGoldman Sachs & Co. LLC
Earlier 8-K filings
Showing 10 of 24 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Viatris with the Signal API
One POST /v1/companies/enrich call with viatris.com returns Viatris 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Viatris 8-K
When did Viatris file its latest 8-K?
What did Viatris disclose in its latest 8-K?
Where can I read Viatris's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .